High-Risk Melanoma: Considerations for Practice Sanjiv S. Agarwala, MD Professor of Medicine Temple University School of Medicine Chief, Oncology & Hematology St Luke’s…

Slide 1Major Cancer Milestones Slide 2 1970–1979 Slide 3 Major Cancer Milestones 1970–1979 Early 1970s: Increased use of radioactive ''seeds'' to…

Slide 1Progress Against Melanoma Slide 2 1970–1979 Slide 3 Progress Against Melanoma 1970–1979 1978: Hereditary syndrome linked to increased melanoma risk Slide 4 Progress…

1. Breaking Tolerance to Invoke an Immune Response to Cancer (Melanoma)Introduction:This paper is dedicated to all the Melanoma Patients that aren’t here today but wereinstrumental…

1. What To Look For in Peregrine’s Q2 Earnings 2. Big Bet on Immunotherapy • Peregrine is developing bavituximab – Phase 3 trial in second-line non-small cell lung…

1. CONTROLLING THE KNOWN VARIABLES Strategies for solving the operational challenges of oncology clinical trials EXECUTIVE BRIEF 2. The Promise of Personalized Medicine •…

Background Journal Club Ranjita Pallavi Fellow 1 Department of Hematology/Oncology Westchester Medical Center Introduction Despite recent advances such as the anti-cytotoxic…

Melanoma Immunotherapy Patrick Hwu, MD Professor and Chairman Melanoma Medical Oncology Saturday, January 31, 2015 If Not Removed at an Early Stage Melanoma Can Spread Throughout…

Red Chip Presentation April 23 , 2015 NASDAQ: GALT www.galectintherapeutics.com © 2015 Galectin Therapeutics Inc. 2© 2015 Galectin Therapeutics | NASDAQ:GALT This presentation…

1. Accelerating Drug Development through Drug & Companion Diagnostic Co-Development Mark Roberts PhD Director, Diagnostics Development Covance Central Laboratory ServicesCONFIDENTIAL…